Analyst Expectations for Marinus Pharma's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided ratings for Marinus Pharma (NASDAQ:MRNS) in the last quarter, with 3 bullish, 4 somewhat bullish, and no bearish ratings. The average price target is $25.43, compared to the current price of $10. The previous average price target was $30.
June 23, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marinus Pharma has received 7 positive analyst ratings in the last quarter, with an average price target of $25.43, implying an upside from the current price of $10.
The 7 positive analyst ratings for Marinus Pharma indicate a bullish sentiment towards the stock. The average price target of $25.43 is significantly higher than the current price of $10, suggesting that analysts believe the stock has potential for growth in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100